Peruvian (BVL) Pharma Industry Analysis
UpdatedApr 29, 2024
DataAggregated Company Financials
Companies1
- 7D-5.5%
- 3M34.8%
- 1Y34.8%
- YTDn/a
Over the last 7 days, the Pharma industry has dropped 5.5%, driven by pullbacks from every company within the industry. Over the past 12 months, the industry was up 35%.
Industry Valuation and Performance
Has the Peruvian Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 30 Apr 2024 | S/279.7m | S/337.5m | S/12.0m | 23.2x | 23.2x | 0.8x |
| Thu, 28 Mar 2024 | S/295.9m | S/337.5m | S/12.0m | 24.6x | 24.6x | 0.9x |
| Sat, 24 Feb 2024 | S/213.5m | S/337.5m | S/12.0m | 17.7x | 17.7x | 0.6x |
| Mon, 22 Jan 2024 | S/207.6m | S/338.9m | S/4.4m | 47.2x | 47.2x | 0.6x |
| Wed, 20 Dec 2023 | S/207.6m | S/338.9m | S/4.4m | 47.2x | 47.2x | 0.6x |
| Fri, 17 Nov 2023 | S/207.6m | S/338.9m | S/4.4m | 47.2x | 47.2x | 0.6x |
| Sun, 15 Oct 2023 | S/207.6m | S/344.4m | -S/3,335,000.00 | n/a | -62.2x | 0.6x |
| Tue, 12 Sep 2023 | S/207.6m | S/344.4m | -S/3,335,000.00 | n/a | -62.2x | 0.6x |
| Thu, 10 Aug 2023 | S/207.6m | S/344.4m | -S/3,335,000.00 | n/a | -62.2x | 0.6x |
| Sat, 08 Jul 2023 | S/207.6m | S/335.8m | S/465.0k | 446.5x | 446.5x | 0.6x |
| Mon, 05 Jun 2023 | S/207.6m | S/376.2m | S/26.6m | 7.8x | 7.8x | 0.6x |
| Wed, 03 May 2023 | S/207.6m | S/376.2m | S/26.6m | 7.8x | 7.8x | 0.6x |
| Fri, 31 Mar 2023 | S/207.6m | S/363.8m | S/11.5m | 18x | 18x | 0.6x |
| Sun, 26 Feb 2023 | S/207.6m | S/363.8m | S/11.5m | 18x | 18x | 0.6x |
| Tue, 24 Jan 2023 | S/207.6m | S/363.8m | S/11.5m | 18x | 18x | 0.6x |
| Thu, 22 Dec 2022 | S/207.6m | S/363.8m | S/11.5m | 18x | 18x | 0.6x |
Price to Earnings Ratio
18x
Current Industry PE
- There is only one company in the Peruvian Pharmaceuticals industry, so there is insufficient data to make an industry-wide assessment of both the PE and PS ratio.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
- Meanwhile revenues for these companies have declined 2.5% per year.
- This means that the cost of doing business could be reducing since sales have declined but profits have remained steady.
Industry Comparison
How does Peruvian Pharma compare with similar industries?
| PE Market | 0.66% | |
| Healthcare | -5.47% | |
| Pharma | -5.47% | |
| Pharma | -5.47% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| No data available | |||||